Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Astellas Pays $125 Million Up-Front To Share Rights To AVEO's Tivozanib

Feb 17 2011

• By PharmAsia News

Related Content

Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately

Nov 25 2009

Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration

Oct 30 2009

Astellas Wins OSI But Victory Comes At A Price

May 17 2010

Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out

Jun 21 2010

More from Archive

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window